In one of Aesop’s fables a vixen and lioness were talking to each other about their young. The fox boasted to the lioness that where she had given birth to a litter of cubs each time, the lioness had only given birth to one tiny cub. “But that one is a lion” responded the lioness.
In the world of orphan diseases, as companies prepare to launch their new innovations, the challenge is to find the small number of authentic opinion leaders, thinkers, experts and clinicians in the field. In other words, the lions who through their knowledge, expertise and influence, can help others accept, grow in confidence and ultimately use a new treatment in clinical practice.
Research undertaken by MMRG shows that in most markets, the total number of orphan disease Key Opinion Leaders (KOLs) amounts to no more than 10. So in the same way as the vixen was reminded that quality is better than quantity, the challenge for companies preparing to launch a new orphan drug is, are you focused on quality or quantity?
Download this whitepaper to discover the results of MMRG’s research.
MMRG will be joining us at this year’s World Orphan Drug Congress USA 2015. Haven’t registered yet? It’s not too late too join them. Visit www.terrapinn.com/orphandrug